Background: Nicobrevin is a proprietary product marketed as an aid to smoking cessation. It contains quinine, menthyl valerate, camphor and eucalyptus oil.
Objectives: The objective of this review was to assess the effects of Nicobrevin on long term smoking cessation
Search strategy: We searched the Cochrane Tobacco Addiction Group trials register.
Selection criteria: Randomized trials comparing Nicobrevin to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow up.
Data collection and analysis: Data were sought on the outcome, method of randomization, and completeness of follow up.
Main results: We identified no trials meeting the full inclusion criteria including long-term follow up.
Authors' conclusions: There is no evidence available from long-term trials that Nicobrevin can aid smoking cessation.